EUVIMEDEUVIMED entdecken
Open Access

N -Methyl- d -Aspartate Receptor Antibody and Sensory Gating Deficits in Non-smoking, Minimal Antipsychotic Medication Exposure, and First-Episode Patients With Schizophrenia

Jinghui Tong, Kebing Yang, Wei Li, Leilei Wang, Yi Yin, Yanfang Zhou, Junchao Huang, Ping Zhang, Yanli Zhao, Song Chen, Hongzhen Fan, Yimin Cui und 8 weitere

Schizophrenia Bulletin · 2025

DOI: 10.1093/schbul/sbae180 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Schizophrenia Bulletin, 2025. Verfasst von Jinghui Tong und 19 weiteren Autor:innen. Beteiligte Einrichtung: Peking University HuiLongGuan Clinical Medical School, Beijing Huilongguan Hospital, Beijing 100096, China. Hauptthemen laut MEDLINE: Schizophrenia, Receptors, N-Methyl-D-Aspartate, Sensory Gating, Evoked Potentials, Auditory. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, High level public health talents-leading talents project, NIMH NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Hypothesis Sensory gating deficit is considered a pathophysiological feature of schizophrenia, which has been linked to N-methyl-d-aspartate receptor (NMDAR) hypofunction as one of the potential underlying mechanisms. Here, we hypothesize that higher levels of NMDAR antibody (Ab) may contribute to the sensory gating deficits in schizophrenia. Study Design We enrolled 72 non-smoking inpatients with first-episode schizophrenia (FES), most of them with only a relatively short duration of exposure to antipsychotic medications, and 51 non-smoking healthy controls (HC). Sensory gating was measured by P50 evoked potentials ratio and the difference between the two stimuli in an auditory paired-stimuli paradigm and serum NMDAR Ab levels were quantified by enzyme-linked immunosorbent assay. Study Results The FES group showed higher serum NMDAR Ab levels [(9.23 ± 4.15) ng/mL vs. (7.08 ± 2.83) ng/mL; P = .002], higher P50 ratio (P = .002), and less P50 difference (P = .001) than HC. In partial correlation analysis, serum NMDAR Ab levels were positively correlated with the P50 ratio (r = 0.36, P = .003) and negatively with the P50 difference (r = −0.39, P = .001) in the FES group. The NMDAR Ab levels mediated the diagnosis of schizophrenia and P50 sensory gating deficits (P50 ratio and P50 difference). Conclusions Autoimmunity targeting NMDAR is a crucial intermediate mechanism in impaired sensory gating in patients with schizophrenia. The findings support early intervention targeting NMDAR for patients with schizophrenia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SchizophreniaReceptors, N-Methyl-D-AspartateSensory GatingEvoked Potentials, AuditoryAntipsychotic AgentsAutoantibodiesHumansMaleFemaleAdultYoung AdultAdolescent

Stichwörter der Autor:innen

NMDAR antibodyfirst episode schizophreniamediation analysissensory gating deficits

Substanzen

Receptors, N-Methyl-D-AspartateAntipsychotic AgentsAutoantibodies

Autor:innen und Institutionen

  • Peking University HuiLongGuan Clinical Medical School, Beijing Huilongguan Hospital, Beijing 100096, China.
  • Department of Pharmacy, Peking University First Hospital, Beijing 100034, China.
  • Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06510, United States.
  • Department of Psychiatry and Behavioral Sciences, University of Texas Health Science Center, Houston, TX 77030, United States.

ORCID-Profile: Chiang-Shan R Li, Yunlong Tan

Förderung

  • NIH HHS
  • High level public health talents-leading talents project
  • NIMH NIH HHS
  • National Natural Science Foundation of China
  • Capital Health Research and Development of Special
  • High level public health talents—leading talents project
  • National Institutes of Health

Zitieren

APA

Tong, J., Yang, K., Li, W., Wang, L., Yin, Y., Zhou, Y., Huang, J., Zhang, P., Zhao, Y., Chen, S., Fan, H., Cui, Y., Luo, X., Tan, S., Wang, Z., Feng, W., Tian, B., Li, C. R., Hong, L. E., & Tan, Y. (2025). N -Methyl- d -Aspartate Receptor Antibody and Sensory Gating Deficits in Non-smoking, Minimal Antipsychotic Medication Exposure, and First-Episode Patients With Schizophrenia. Schizophrenia Bulletin. https://doi.org/10.1093/schbul/sbae180

Vancouver

Tong J, Yang K, Li W, Wang L, Yin Y, Zhou Y, et al. N -Methyl- d -Aspartate Receptor Antibody and Sensory Gating Deficits in Non-smoking, Minimal Antipsychotic Medication Exposure, and First-Episode Patients With Schizophrenia. Schizophrenia Bulletin. 2025. doi:10.1093/schbul/sbae180

BibTeX
@article{Tong2025,
  author = {Tong, Jinghui and Yang, Kebing and Li, Wei and Wang, Leilei and Yin, Yi and Zhou, Yanfang and Huang, Junchao and Zhang, Ping and Zhao, Yanli and Chen, Song and Fan, Hongzhen and Cui, Yimin and Luo, Xingguang and Tan, Shuping and Wang, Zhiren and Feng, Wei and Tian, Baopeng and Li, Chiang-Shan R and Hong, L Elliot and Tan, Yunlong},
  title = {N -Methyl- d -Aspartate Receptor Antibody and Sensory Gating Deficits in Non-smoking, Minimal Antipsychotic Medication Exposure, and First-Episode Patients With Schizophrenia},
  journal = {Schizophrenia Bulletin},
  year = {2025},
  doi = {10.1093/schbul/sbae180}
}
Kostenlos starten →